Background: Delays in treatments are frequent in real-world lymphoma management. This study evaluates the impact of diagnosis-to-treatment intervals (DTIs) and first inter-cycle delay (IcD) on outcomes in patients with Hodgkin lymphoma (HL) receiving ABVD chemotherapy. Methods: We retrospectively analyzed 137 patients with classical HL treated with ABVD at a single institution between 2015 and 2022. Results: The median age was 34 years (range: 18–73), and 62% were male. The median DTI was 14 days, with 24.1% of patients experiencing a delay of >7 days between the first and second chemotherapy cycles. The most frequent reason for delay was neutropenia, observed in 69% of delayed cases. Neither DTI nor IcD was significantly associated with PFS or OS. Multivariate analysis identified elevated beta-2 microglobulin as an independent predictor of both inferior PFS and OS. Conclusions: This is the first study to evaluate both DTI and first IcD as independent prognostic factors in HL. Modest delays in treatment initiation or early cycle administration did not negatively affect survival. Timely but flexible scheduling of ABVD may be appropriate in HL. Prospective studies are warranted in the era of novel therapeutic agents.
18 April 2026 in Clinics and Research in Hepatology and Gastroenterology
Background/Objectives: Cabazitaxel is an established treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC), but outcomes beyond the conventional 10-cycle threshold remain incompletely characterized. This threshold largely reflects clinical trial design. We therefore evaluated outcomes associated with cabazitaxel treatment beyond 10 cycles using a predefined 8-month landmark analysis intended to reduce early immortal time bias. Methods: This retrospective single-center study included 98 patients with mCRPC treated with cabazitaxel between 2010 and 2020. The final cohort comprised 74 patients who were alive at the predefined 8-month landmark. The primary endpoint was overall survival (OS) from the landmark, and secondary endpoints included conditional radiologic progression-free survival (rPFS), conditional prostate-specific antigen progression-free survival (PSA-PFS), treatment response, and safety. Results: Among the 74 patients included in the landmark cohort, 45 (60.8%) ultimately received ≤10 cycles and 29 (39.2%) received >10 cycles. The median landmark OS was numerically longer in the >10-cycle group (17.6 vs. 10.4 months; p = 0.123). Conditional rPFS and PSA-PFS did not differ significantly between groups (>10 vs. ≤10 cycles: 4.4 vs. 2.3 months; p = 0.255 and 4.2 vs. 2.2 months; p = 0.137, respectively). In a broader baseline-adjusted sensitivity model, the treatment duration association was not statistically significant (HR for ≤10 vs. >10 cycles, 1.58; 95% CI, 0.91–2.74; p = 0.105). The crude cumulative proportions of grade ≥3 neutropenia and febrile neutropenia were higher in the >10-cycle group. Conclusions: Cabazitaxel treatment beyond 10 cycles appeared feasible in selected patients. However, future-derived exposure classification and responder enrichment limit causal interpretation. The survival association was not consistently maintained across sensitivity analyses, supporting a hypothesis-generating interpretation rather than evidence of a survival benefit from continuation beyond 10 cycles.